SKYRIZI has

99% PREFERRED* COVERAGE FOR COMMERCIAL Ps PATIENTS2

PREFERRED COMMERCIAL COVERAGE FOR PATIENTS WITH Ps2

National Preferred Commercial Coverage

Preferred Medicare Part D

99%

95%

National commercial health plan formulary status under the pharmacy benefit updated as of January 2022.2

If you have determined that SKYRIZI is the appropriate treatment, preferred* access could mean:

EXCEPTIONAL access

for commercial patients

Standard PRIOR AUTHORIZATION (PA) and appeal processes

potential for one-time PA/appeal approval

>95% OF COMMERCIAL PATIENTS HAVE ACCESS TO SKYRIZI FOR PsA2

ABBVIE IS COMMITTED TO ACHIEVING THE SAME FORMULARY STATUS FOR Ps AND PsA

National commercial coverage as of January 2022

BRIDGE PROGRAM ELIGIBILITY

Product available for eligible, commercially insured patients during the appeal process due to step therapy requirement

SKYRIZI® is the #1 prescribed biologic in new and switching plaque psoriasis patients.

As of 10/2021. New patients defined as bio-naïve; switch patients defined as bio-experienced switching biologics. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP) through proprietary method on diagnosis classification.

Encourage your patients to enroll in

Affordability

Commercially insured patients may pay as little as $5 per quarterly dose§

One-to-one support

Nurse Ambassadors

Access

Insurance specialists are there to help your patients navigate their coverage

*Preferred means the product is placed on the plan’s preferred formulary tier. Preferred products may also require a step edit depending on the product’s label. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier.

Commercial insurance coverage varies by type and plan. Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

§Terms and Conditions apply. This benefit covers SKYRIZI® (risankizumab-rzaa). Eligibility: Available to patients with commercial prescription insurance coverage for SKYRIZI who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the Skyrizi Complete Savings Card and patient must call Skyrizi Complete at 1.866.SKYRIZI to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the Skyrizi Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html.

Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

Stay up to date on the latest SKYRIZI news and information


Enroll patients in SKYRIZI complete

Resources for your patients

Helpful resources for your practice &
your patients

SKYRIZI resources